California medical device firm TriReme Medical, which also has offices in Singapore, announced Tuesday that it has raised $18 million.
The round was led by Luminor Capital, a Singaporean private equity firm, new Asian investors as well as existing investors. The company’s board includes representatives from Adams Street Partners, Three Arch Partners, Bio*One Capital and EDB Investments.
The company makes minimally invasive coronary and peripheral devices for the treatment of complex lesions and the money raised will be used to support the development of the company’s dilation catheters as well as to expand its commercial infrastructure globally.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
“We are thrilled to have this major support from Asia in our efforts to create a next generation of interventional devices, ” said Eitan Konstantino, president and CEO of TriReme Medical, in a news release.
According to TriReme’s website, the company makes several dilation catheters: the Chocolate, GliderXtreme and GliderfleX PTA balloon catheters, which are part of its peripheral devices while its Antares Coronary Stent system and its Glider PTCA balloon catheters form its coronary products.
[Photo Credit: Pile of Money from Big Stock Photo]
